Cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE)4 is an intracellular target that can be exploited to the treat chronic obstructive pulmonary disease (COPD), given that it is expressed in all inflammatory cells implicated in this inflammatory airways disease. At the present time, roflumilast is the only PDE4 inhibitor that has received regulatory approval for use in patients with COPD.
Cazzola, M., Calzetta, L., Rogliani, P., Matera, M. (2016). The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. EXPERT OPINION ON DRUG DISCOVERY, 11(7), 733-744 [10.1080/17460441.2016.1184642].
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease
CAZZOLA, MARIO;ROGLIANI, PAOLA;
2016-01-01
Abstract
Cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE)4 is an intracellular target that can be exploited to the treat chronic obstructive pulmonary disease (COPD), given that it is expressed in all inflammatory cells implicated in this inflammatory airways disease. At the present time, roflumilast is the only PDE4 inhibitor that has received regulatory approval for use in patients with COPD.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
